Fig. 4: Distinct features of tumors with EGFR or ERBB2 mutation subtypes.

EGFR-mutant and ERBB2-mutant IAC had distinct concurrent mutations compared to their AIS counterpart. Bar plots at the top illustrate the distribution of detection rate for each mutation subtypes for EGFR (i.e. L858R, exon 19 deletion (19del), and exon 20 insertion (20ins)) (A) and ERBB2 (i.e. 20ins, copy number amplification (CN amp), and other non-20ins, non-CNamp mutations) (B) across AIS, MIA, and IAC. The co-occurrence fraction below panel A denotes the percentage of co-occurring mutations for each mutation subtype. Heat maps at the bottom summarize the mutations in genes involved in key signaling pathways of the patients with AIS, MIA, and IAC who harbored certain mutation subtypes of EGFR (A) and ERBB2 (B). Patients harboring certain EGFR (C) or ERBB2 (D) mutation subtypes had different age of onset (top) and had distinct mutation counts (bottom) across tumor invasion levels.